Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks.

ABSTRACT:

Background and aims

Few recent large-scale studies have evaluated the risks and benefits of continuing oral anticoagulant (OAC) therapy after catheter ablation (CA) for atrial fibrillation (AF). This study evaluated the status of continuation of OAC therapy and the association between continuation of OAC therapy and thromboembolic and bleeding events according to the CHADS2 score.

Methods

This retrospective study included data from the Japanese nationwide administrative claims database of patients who underwent CA for AF between April 2014 and March 2021. Patients without AF recurrence assessed by administrative data of the treatment modalities were divided into two groups according to continuation of OAC therapy 6 months after the index CA. The primary outcomes were thrombo

SUBMITTER: Kanaoka K 

PROVIDER: S-EPMC10873714 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature